Identifying pathogenic alterations in cancer susceptibility genes is critical for guiding patient management as genetic diagnoses influence surveillance strategies, preventive measures, surgical decision-making, and therapeutic approaches, such as the use of PARP inhibitors in BRCA1/2 mutation carriers [1,3,4]. The gene discussed is BRCA1; the disease is cancer.